Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE

By Chesnut Charles H.   Ettinger Mark P.   Miller Paul D.   Baylink David J.   Emkey Ronald   Harris Steven T.   Wasnich Richard D.   Watts Nelson B.   Schimmer Ralph C.   Recker Robert R.  

Current Medical Research and Opinion, Vol. 21, Iss. 3, 2005-03 ,pp. : 391-402

Informa Healthcare

Access to resources Recommend Favorite

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

By Recker R.   Weinstein R.   Chesnut C.   Schimmer R.   Mahoney P.   Hughes C.   Bonvoisin B.   Meunier P.  

Osteoporosis International, Vol. 15, Iss. 3, 2004-03 ,pp. : 231-237

Springer Publishing Company

Access to resources Recommend Favorite

Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

By  

Oncology Research and Treatment, Vol. 35, Iss. 6, 2012-05 ,pp. : 380-387

Karger

Access to resources Recommend Favorite

Renal Toxicity following Zoledronic Acid Reversed with Ibandronate in a Prostate Cancer Patient with Bone Metastases

By  

Urologia Internationalis, Vol. 80, Iss. 4, 2008-06 ,pp. : 448-450

Karger

Access to resources Recommend Favorite

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

By Delmas P.   Recker R.   Chesnut C.   Skag A.   Stakkestad J.   Emkey R.   Gilbride J.   Schimmer R.   Christiansen C.  

Osteoporosis International, Vol. 15, Iss. 10, 2004-10 ,pp. : 792-798

Springer Publishing Company

Access to resources Recommend Favorite